24. Abdominal CT

Hepatic CT interpretation begins from the organ's dual blood supply, because nearly every diagnostic sign in the liver is a statement about the relative timing of hepatic arterial and portal venous inflow. The normal parenchyma derives roughly three-quarters of its perfusion from the portal vein, so it enhances maximally in the portal-venous phase ($\approx 60$–$80$ s after injection) to roughly $100$–$120\,\text{HU}$, whereas lesions that recruit a dominant arterial supply declare themselves on the late arterial phase ($\approx 35$ s). This is the physiologic engine of $\textbf{LI-RADS version 2018}$, the governing framework for the at-risk liver (cirrhosis, chronic hepatitis B, or current/prior hepatocellular carcinoma). Hepatocellular carcinoma (HCC) arises through stepwise hepatocarcinogenesis in which a regenerative nodule loses its portal supply and acquires unpaired arteries (neoangiogenesis); the imaging correlate is $\textbf{nonrim arterial-phase hyperenhancement}$ followed by $\textbf{nonperipheral washout}$ — relative hypoenhancement against the background parenchyma on portal-venous or delayed phases as the lesion's high arterial inflow drains and the surrounding liver opacifies. An enhancing $\textbf{capsule}$, $\textbf{threshold growth}$ ($\geq 50\%$ in $\leq 6$ months), and size complete the major-feature set; their combination determines the LR-1 (definitely benign) through LR-5 (definitely HCC) category, and an LR-5 lesion may be treated as HCC without biopsy. The systematic search reads each phase as a separate question: the arterial phase localizes hypervascular lesions, the portal-venous phase establishes washout and detects hypovascular metastases as low-attenuation foci against bright parenchyma, and a delayed/equilibrium phase confirms washout and the capsule.

The ranked differential is dominated by pretest probability. In a non-cirrhotic liver, an incidental arterially enhancing lesion is far more likely benign: a $\textbf{hemangioma}$ shows discontinuous, peripheral, nodular enhancement that follows the blood pool and progressively fills in, while $\textbf{focal nodular hyperplasia}$ enhances avidly and homogeneously in the arterial phase, becomes nearly isoattenuating later, and may display a central scar. $\textbf{Hepatic adenoma}$, tied to estrogen exposure and glycogen-storage disease, is heterogeneous and prone to hemorrhage. In a patient with a known extrahepatic primary, by contrast, the same hypoattenuating lesion is metastatic until proven otherwise; hypervascular metastases (neuroendocrine, renal, melanoma, thyroid) mimic HCC on the arterial phase, and the discriminator is clinical context plus the washout pattern. Diffuse disease is read by attenuation: hepatic $\textbf{steatosis}$ lowers parenchymal density (an unenhanced liver attenuation more than $10\,\text{HU}$ below spleen, or an absolute value below $\approx 40\,\text{HU}$, is diagnostic), whereas iron overload and amiodarone raise it.

The failure modes couple physics and cognition. $\textbf{Transient hepatic attenuation differences}$ — wedge-shaped arterial-phase enhancement from altered portal flow (e.g., portal vein compression or thrombosis) — masquerade as hypervascular lesions but lack a mass and resolve on later phases. $\textbf{Pseudolesions}$ at the gallbladder fossa and falciform ligament reflect aberrant venous drainage. Suboptimal bolus timing or a slow circulation can blunt arterial enhancement and hide an HCC, and a focal fatty area or focal sparing simulates a lesion until its non-mass-like geometry and lack of distortion of vessels are recognized. Cognitively, satisfaction of search after a dominant mass causes a second lesion to be missed, and anchoring on "cirrhosis equals HCC" risks overcalling a benign arterial pseudoenhancement as malignancy.

Gallbladder disease on CT is read as a problem of wall integrity, luminal content, and pericholecystic physiology, with the recognition that CT is less sensitive than ultrasound for the calculi themselves — only a minority are sufficiently calcified to be conspicuous, and many are isoattenuating to bile. The dominant entity, $\textbf{acute calculous cholecystitis}$, begins with cystic-duct obstruction by a stone, producing bile stasis, mucosal injury, and mural inflammation; the CT correlates are gallbladder distension (short-axis diameter $> 4$ cm), wall thickening ($> 3$ mm), mural hyperenhancement and a hypoattenuating edematous wall, pericholecystic fat stranding, and pericholecystic fluid. These imaging features map onto the $\textbf{Tokyo Guidelines (TG18)}$ diagnostic criteria, which combine local inflammatory signs, systemic inflammation, and imaging to establish the diagnosis and then grade severity, directly informing the urgency of cholecystectomy versus percutaneous cholecystostomy. A key sign of impending complication is hyperemia of adjacent hepatic parenchyma in the arterial phase, reflecting transmural inflammation. The systematic search interrogates the wall (thickness, layered edema, focal discontinuity), the lumen (stones, sludge, gas, hemorrhage), the pericholecystic space (fluid, abscess, fat stranding), and the adjacent liver (reactive hyperenhancement, abscess).

The differential is stratified by the consequence of missing it. $\textbf{Gangrenous cholecystitis}$ — the most common complication, driven by mural ischemia as intraluminal pressure exceeds perfusion — is signaled by an irregular, poorly enhancing or frankly non-enhancing wall, intraluminal membranes (sloughed mucosa), and intraluminal hemorrhage; its recognition mandates urgent surgery because of the risk of perforation. $\textbf{Emphysematous cholecystitis}$, disproportionately affecting diabetic and immunocompromised patients and caused by gas-forming organisms, shows gas within the wall or lumen and is a surgical emergency with high mortality; CT is far more sensitive than ultrasound for this intramural gas. $\textbf{Gallbladder perforation}$ produces a focal wall defect (the "hole sign") with a pericholecystic collection. Against these, $\textbf{wall thickening is profoundly nonspecific}$: a Bayesian reading recognizes that in a patient with hypoalbuminemia, heart failure, cirrhosis with ascites, hepatitis, or simply a contracted post-prandial gallbladder, mural thickening reflects edema or physiologic contraction rather than cholecystitis, and the absence of fat stranding and the clinical context lower the posterior probability accordingly. $\textbf{Gallbladder carcinoma}$ presents as focal or asymmetric wall thickening, an intraluminal mass, or a mass replacing the fossa and invading the liver, and porcelain (calcified-wall) gallbladder and large polyps raise its prior.

The failure modes are instructive. CT readily misses the obstructing stone, so a normal-appearing lumen does not exclude cholecystitis; conversely, the most consequential cognitive trap is $\textbf{anchoring on a thickened wall}$ and labeling cholecystitis in a patient whose thickening is from diffuse third-spacing, while overlooking the actual diagnosis. Partial-volume averaging through the gallbladder neck simulates a stone, and a contracted gallbladder after a meal mimics chronic disease. Satisfaction of search after identifying cholelithiasis can cause the subtle gangrenous signs — discontinuous mucosal enhancement, intraluminal membranes — to be overlooked, deferring an operation that is time-critical.

Pancreatic CT is dominated by two problems whose imaging diverges sharply: the inflamed gland of pancreatitis and the solid or cystic neoplasm. $\textbf{Acute pancreatitis}$ is the autodigestive consequence of prematurely activated proteases; the pivotal interpretive task, formalized by the $\textbf{revised Atlanta classification (2012)}$, is to separate $\textbf{interstitial edematous pancreatitis}$ — a uniformly or near-uniformly enhancing, edematous gland with peripancreatic fat stranding — from $\textbf{necrotizing pancreatitis}$, defined by non-enhancement of pancreatic parenchyma on contrast-enhanced CT, reflecting microvascular thrombosis and tissue death. Because necrosis evolves, the optimal timing for assessing its extent is $72$ h or more after onset; imaging too early underestimates it. The $\textbf{CT Severity Index (Balthazar)}$ couples the degree of inflammation and the number of peripancreatic collections with the percentage of necrosis to generate a score that correlates with morbidity and mortality, anchoring prognosis. Collections are then named by age and content: an early ($< 4$ weeks) homogeneous fluid collection without a wall in interstitial disease is an $\textbf{acute peripancreatic fluid collection}$, which after $\approx 4$ weeks and encapsulation becomes a $\textbf{pseudocyst}$; the necrotic counterparts are the heterogeneous $\textbf{acute necrotic collection}$ and the encapsulated $\textbf{walled-off necrosis}$, the distinction being critical because walled-off necrosis contains solid debris and is not amenable to simple aspiration. Vascular complications — splenic vein thrombosis, splenic-artery pseudoaneurysm — and the presence of gas (infected necrosis) are searched deliberately because they redirect management toward intervention.

$\textbf{Pancreatic ductal adenocarcinoma}$ is read on a dedicated dual-phase protocol because the tumor is desmoplastic and hypovascular: it is most conspicuous as a hypoattenuating, poorly enhancing mass against the better-enhancing normal gland on the $\textbf{pancreatic parenchymal phase}$ ($\approx 40$–$50$ s), and the secondary sign of an abrupt, obstructed pancreatic duct with upstream parenchymal atrophy (the double-duct sign when the common bile duct is also obstructed) may be the only finding of a small isoattenuating tumor. Resectability hinges on vascular contact: the search systematically grades tumor abutment of the celiac axis, superior mesenteric artery, common hepatic artery, superior mesenteric vein, and portal vein, distinguishing borderline-resectable from locally advanced disease and detecting hepatic and peritoneal metastases. Cystic lesions are stratified by their communication with the duct and morphology — a $\textbf{side-branch IPMN}$ communicates with the duct and harbors worrisome features (mural nodule, main-duct dilation, size) that, per European and international guidelines, drive surveillance versus resection; a $\textbf{mucinous cystic neoplasm}$ is a thick-walled lesion in the body/tail of women; a $\textbf{serous cystadenoma}$ is a microcystic, sometimes centrally calcified, benign lesion.

The failure modes are characteristic. A small isoattenuating adenocarcinoma can be invisible except for ductal cutoff, so secondary signs must be hunted. Pancreatitis-related inflammatory mass and autoimmune (IgG4) pancreatitis with its sausage-shaped gland and halo mimic carcinoma. Pseudoenhancement and beam hardening from adjacent contrast or bowel gas degrade pancreatic attenuation measurements, and satisfaction of search after identifying pancreatitis risks missing an underlying obstructing tumor or a developing pseudoaneurysm.

The spleen is interpreted with constant attention to its peculiar enhancement physiology, because the single most common pitfall is mistaking normal for pathologic. In the $\textbf{arterial and early portal-venous phases}$, the spleen enhances heterogeneously in a serpiginous, "zebra" or arciform pattern produced by differential flow through the open and closed compartments of the red pulp; this $\textbf{normal heterogeneity}$ resolves to uniform enhancement by the later portal-venous phase ($\approx 70$ s), which is therefore the correct phase to characterize a splenic lesion and to avoid calling a laceration or infarct on an arterial-phase image. The systematic search assesses size (craniocaudal length $> 13$ cm defines splenomegaly), parenchymal homogeneity on an equilibrated phase, the contour for capsular disruption, the hilar vessels, and the perisplenic space for fluid or hemorrhage. Splenomegaly itself is a Bayesian signpost: in the right context it points to portal hypertension, hematologic malignancy, infiltrative disease, or infection, reframing the search.

Focal splenic disease is ranked by clinical setting. A $\textbf{splenic infarct}$, from emboli (atrial fibrillation, endocarditis), a hypercoagulable state, or sickle cell disease, appears as a peripheral, wedge-shaped, non-enhancing region with its base at the capsule and apex toward the hilum — the geometry follows the segmental arterial supply. $\textbf{Abscesses}$ (pyogenic, or in the immunocompromised, fungal microabscesses) are hypoattenuating, sometimes gas-containing or multifocal lesions accompanied by fever. Cystic lesions span benign epithelial and post-traumatic pseudocysts. Solid masses are uncommon: lymphoma is the most frequent malignancy, producing splenomegaly or hypoattenuating nodules, and metastases (melanoma, breast, lung, ovary) are rare and usually late. The traumatic spleen is graded with the $\textbf{AAST 2018 organ injury scale}$, which integrates laceration depth, hematoma size, and — importantly in the modern revision — the presence of a $\textbf{vascular injury}$: a contained pseudoaneurysm or arteriovenous fistula (a focal rounded collection of contrast that follows the blood pool) and $\textbf{active extravasation}$ (an irregular jet of contrast that increases on delayed images and exceeds aortic attenuation) elevate the grade and shift management toward angioembolization or surgery rather than observation.

The failure modes are dominated by phase. The arching arterial-phase heterogeneity is the classic mimic of laceration and infarct and is dispelled by examining the equilibrated phase; perisplenic clot can be misread as parenchymal injury. Conversely, $\textbf{splenosis}$ and accessory spleens (splenules) simulate masses or peritoneal implants but follow splenic attenuation through all phases. Beam hardening from the adjacent ribs and contrast in the stomach degrades the periphery. Cognitively, in trauma the most consequential error is failing to distinguish a pseudoaneurysm or active bleed from clotted blood, because the former demands intervention; satisfaction of search after the splenic injury also risks missing concomitant left-sided injuries (rib fractures, left renal injury, diaphragmatic rupture).

The adrenal gland is the organ where CT most often converts an incidental finding into a precise probabilistic statement, because the dominant lesion — the lipid-rich adenoma — has an exploitable physical property. Cortical adenomas accumulate intracytoplasmic lipid, which lowers their attenuation; on $\textbf{unenhanced CT}$, a homogeneous adrenal mass measuring $\leq 10\,\text{HU}$ is diagnostic of a lipid-rich adenoma with a specificity around $98\%$, and no further imaging is needed. The remaining lipid-poor adenomas and many other lesions overlap in unenhanced density, so the $\textbf{washout protocol}$ resolves them by exploiting the rapid contrast washout of adenomas relative to malignancy and pheochromocytoma. Using unenhanced (pre), enhanced ($\approx 60$–$80$ s) and delayed ($15$ min) attenuation, the absolute and relative percentage washout are computed as $\text{APW}=\frac{(\text{enhanced}-\text{delayed})}{(\text{enhanced}-\text{unenhanced})}\times 100\%, \qquad \text{RPW}=\frac{(\text{enhanced}-\text{delayed})}{\text{enhanced}}\times 100\%.$ An $\text{APW}\geq 60\%$ or an $\text{RPW}\geq 40\%$ indicates an adenoma; lower values are indeterminate. The systematic search therefore proceeds: measure unenhanced HU; if $\leq 10$, stop (adenoma); if higher and characterization is needed, obtain the delayed phase and compute washout; assess size and growth; and evaluate the contralateral gland and for extra-adrenal disease.

The differential is ranked by clinical context and morphology. In a patient with no malignancy, a small homogeneous mass is overwhelmingly a benign adenoma, and a $\textbf{myelolipoma}$ is confirmed instantly by the presence of macroscopic fat (regions of $-30$ to $-90\,\text{HU}$). In a patient with a known primary cancer, the prior for $\textbf{metastasis}$ rises substantially, and an indeterminate, heterogeneous, or enlarging mass warrants PET or biopsy. $\textbf{Adrenocortical carcinoma}$ is suggested by large size ($> 4$ cm), heterogeneity with necrosis and calcification, and a low washout; $\textbf{pheochromocytoma}$ classically shows marked enhancement, may be cystic or hemorrhagic, and — a crucial caveat — can demonstrate washout values overlapping adenoma, so biochemical screening, not washout, excludes it when clinically suspected. Size and interval growth are themselves risk markers: lesions larger than $4$ cm and those that grow carry a higher malignant prior and prompt consideration of resection.

The failure modes are quantitative and contextual. Washout calculations are invalidated by an inhomogeneous lesion (necrosis, hemorrhage, macroscopic fat), by placing the region of interest over calcification or the edge, and by inconsistent delayed timing. Pheochromocytoma is the canonical $\textbf{washout false-positive}$, so the protocol must never substitute for plasma or urinary metanephrines when the diagnosis is entertained, particularly before biopsy, which is hazardous in unsuspected pheochromocytoma. A normal limb of the gland or a tortuous splenic vessel can simulate a nodule. The principal cognitive error is anchoring on "benign adenoma" for any small adrenal lesion in an oncologic patient, in whom a heterogeneous or indeterminate nodule deserves dedicated characterization rather than dismissal.

Renal CT divides naturally into the characterization of masses and the evaluation of stone disease and infection, and both rest on multiphase enhancement and true attenuation measurement. The renal phases are deliberate: the $\textbf{corticomedullary phase}$ ($\approx 30$–$40$ s) maps the hypervascular cortex and the renal vessels but can hide a medullary lesion, the $\textbf{nephrographic phase}$ ($\approx 90$–$100$ s) homogenizes the parenchyma and is the most sensitive for detecting and characterizing masses, and the $\textbf{excretory phase}$ opacifies the collecting system for urothelial assessment. The cardinal determination for a solid renal mass is $\textbf{enhancement}$, defined as an increase in attenuation of more than $\approx 20\,\text{HU}$ between unenhanced and nephrographic phases; an enhancing solid mass is renal cell carcinoma until proven otherwise, with the important benign exceptions of $\textbf{angiomyolipoma}$, diagnosed by macroscopic fat ($< -10\,\text{HU}$) in the absence of calcification, and oncocytoma, which cannot be reliably distinguished from carcinoma by imaging. Cystic renal masses are stratified by the $\textbf{Bosniak 2019}$ classification, which grades the wall and septa thickness, the number and character of septa, and the presence of enhancing components into categories I, II, IIF, III, and IV with rising probabilities of malignancy; the update tightened definitions of "enhancement" and septal measurement to reduce the overcalling that committed benign cysts to surgery.

Stone disease is read on unenhanced CT, the reference test: calculi are hyperdense, and the protocol records the maximal diameter, location, and the $\textbf{secondary signs of obstruction}$ — hydroureteronephrosis, perinephric and periureteric stranding, and the soft-tissue "rim sign" around an impacted ureteral stone that distinguishes it from a phlebolith. Stone composition is inferred from attenuation and, on dual-energy CT, from material decomposition that separates uric acid (amenable to dissolution) from calcium-based stones. Infection is interpreted as a perfusion and collecting-system problem: $\textbf{acute pyelonephritis}$ produces striated, wedge-shaped areas of hypoenhancement on the nephrographic phase with perinephric stranding, and progression to a non-enhancing, sometimes gas-containing collection signals a $\textbf{renal abscess}$ or, in the diabetic patient, life-threatening $\textbf{emphysematous pyelonephritis}$, whose intraparenchymal gas pattern dictates urgent drainage or nephrectomy.

The failure modes are both physical and probabilistic. $\textbf{Pseudoenhancement}$ — an artifactual rise of $10$–$20\,\text{HU}$ in a benign cyst caused by beam hardening from surrounding dense contrast — falsely suggests a solid component, particularly in small intrarenal cysts, and is mitigated by recognizing the geometry and by dual-energy techniques. A hyperdense (proteinaceous or hemorrhagic) cyst measures above water on unenhanced images and mimics a solid mass, but does not enhance. Partial-volume averaging across a small cyst spuriously raises its density. Cognitively, the dominant traps are anchoring on a benign-appearing cyst without confirming nonenhancement, satisfaction of search after a stone that causes a coexisting mass to be overlooked, and failing to recognize that in an at-risk patient striated nephrograms and stranding may be the only sign of an obstructing, infected system that constitutes a urologic emergency.

Bowel CT is interpreted through a small set of mechanistic patterns whose meaning depends on the wall layers, the enhancement, and the surrounding mesentery. The normal small-bowel wall is thin ($\leq 3$ mm when distended); $\textbf{wall thickening}$ is the central abnormality, and its pattern discriminates etiology. Inflammatory and ischemic edema produce $\textbf{mural stratification}$ — the "target" or "halo" of a hyperenhancing mucosa and serosa around a hypoattenuating, edematous submucosa — which signals a benign, active process such as Crohn disease, infectious enteritis, or reperfused ischemia; in Crohn disease the thickening is asymmetric and segmental with mucosal hyperenhancement, the "comb sign" of engorged vasa recta, fibrofatty proliferation, and complications of stricture, fistula, and abscess that drive medical versus surgical decisions. By contrast, $\textbf{loss of stratification}$ with homogeneous attenuation and a focal, short, "shouldered" thickening raises the prior for malignancy (adenocarcinoma, lymphoma), and lymphoma characteristically produces marked wall thickening with aneurysmal luminal dilatation rather than obstruction. The systematic search records the segment and length involved, the degree and symmetry of thickening, the enhancement pattern (stratified versus homogeneous, hyper- versus hypoenhancing), the mesenteric reaction (stranding, fluid, engorged vessels, adenopathy), and the luminal caliber upstream and downstream.

Obstruction is read as a search for the $\textbf{transition point}$: a caliber change from dilated proximal bowel ($> 3$ cm small bowel, $> 6$ cm colon, $> 9$ cm cecum) to collapsed distal bowel localizes the lesion, and the differential follows frequency — adhesions (the leading cause of small-bowel obstruction, diagnosed by exclusion at an abrupt transition without a mass), hernias, and tumors. The critical escalation is $\textbf{closed-loop obstruction}$ and strangulation, in which a loop is obstructed at two points and twists about its mesentery; the C- or U-shaped loop, the radial "whirl" of twisted mesenteric vessels, and — most ominously — $\textbf{compromised wall enhancement}$ indicate ischemia and mandate emergent surgery. $\textbf{Pneumatosis}$ (gas within the wall) and $\textbf{portal venous gas}$ are weighed by context: in a hypotensive patient with an acute abdomen they signal transmural infarction, whereas in a stable patient on steroids or with chronic obstructive lung disease they may be benign. Infectious and inflammatory colitides (pseudomembranous, infectious, neutropenic typhlitis, diverticulitis) are localized by distribution and the disproportion between pericolonic stranding and wall thickening.

The failure modes are technical and cognitive. Underdistended or collapsed bowel mimics thickening, so apparent wall abnormality in a non-distended segment must be interpreted cautiously; positive oral contrast can obscure mural hyperenhancement, which is why neutral (water-density) enteric contrast is preferred when mucosal enhancement matters. Peristaltic and respiratory motion blur the wall, and a fluid-filled non-opacified loop simulates a mass. The dominant cognitive errors are satisfaction of search after a transition point — missing a second lesion or the signs of strangulation — and premature closure on "ileus" without scrutinizing for the closed loop and the ischemic wall whose recognition changes the operation from elective to emergent.

The mesentery is the vascular and lymphatic scaffold of the bowel, and its CT interpretation centers on the patency of the mesenteric vessels and the attenuation of the mesenteric fat. $\textbf{Acute mesenteric ischemia}$ is the emergency that organizes this section, and its mechanism dictates its imaging. $\textbf{Arterial embolism}$ (typically from a cardiac source) and $\textbf{arterial thrombosis}$ (superimposed on atherosclerotic ostial disease) produce an abrupt intraluminal filling defect or occlusion of the superior mesenteric artery on CT angiography, with bowel that initially shows diminished, then absent, mural enhancement; $\textbf{venous thrombosis}$ shows an expanded, non-enhancing superior mesenteric or portal vein with mesenteric edema and engorgement and a thickened, often hyperdense (hemorrhagic) bowel wall; and $\textbf{nonocclusive mesenteric ischemia}$, driven by low-flow states and vasoconstriction, shows patent vessels with diffusely diminished bowel enhancement. The $\textbf{WSES framework}$ emphasizes that CT angiography is the diagnostic test and that the constellation of vascular occlusion, decreased or absent bowel-wall enhancement, bowel dilatation, and — late — $\textbf{pneumatosis and portal venous gas}$ should trigger emergent revascularization or resection, because transmural infarction is the lethal endpoint. Decreased wall enhancement is the most specific early sign and is sought deliberately, since wall thickening is a late and nonspecific feature that may even be absent in arterial occlusion (the wall is paper-thin and underperfused).

Beyond ischemia, the mesentery is read by its fat. $\textbf{Misty mesentery}$ — increased attenuation of mesenteric fat — is a nonspecific pattern of edema, inflammation, hemorrhage, or infiltration whose differential is set by context: edema in hypoalbuminemia or portal hypertension, inflammation in pancreatitis or mesenteric panniculitis, and neoplastic infiltration in lymphoma. $\textbf{Sclerosing mesenteritis}$ progresses from misty fat to a soft-tissue mass with a fibrotic pseudocapsule and the "fat ring sign" preserving fat around mesenteric vessels and nodes. A focal mesenteric mass with $\textbf{calcification and a desmoplastic, spiculated reaction}$ in the small-bowel mesentery is the signature of a $\textbf{neuroendocrine (carcinoid) tumor}$ metastasis, which tethers and kinks adjacent bowel. The systematic search assesses the mesenteric vessels (arterial and venous patency, atherosclerotic burden), the fat attenuation and its distribution, mesenteric nodes, and any focal mass or its secondary tethering.

The failure modes are high-stakes. The diagnosis of acute mesenteric ischemia is frequently missed because early bowel changes are subtle and nonspecific and because the arterial defect is not actively sought on the angiographic phase; the consequence of premature closure here is catastrophic. Streak artifact from dense aortic and vascular contrast and from surgical clips degrades the assessment of the SMA origin, and respiratory motion blurs the mesenteric vessels. A normal misty mesentery from recent hypervolemia or a postoperative state is overread as disease, while genuine subtle infiltration is dismissed as artifact. The anchoring trap is attributing an acute abdomen with lactic acidosis to a more common diagnosis (obstruction, pancreatitis) without dedicated scrutiny of mesenteric vascular patency and bowel-wall enhancement.

The peritoneal cavity is interpreted as a fluid-dynamic and surface-coating space, and the first questions are always the attenuation of any fluid, its distribution within the compartmentalized cavity, and whether the peritoneal surfaces and omentum are abnormally thickened or studded. $\textbf{Free fluid}$ is characterized by Hounsfield density: simple ascites and most transudates measure near water ($0$–$15\,\text{HU}$), exudative and infected fluid are higher, and $\textbf{hemoperitoneum}$ is identified by attenuation in the $\approx 30$–$45\,\text{HU}$ range, with the $\textbf{sentinel-clot sign}$ — the highest-attenuation clotted blood lying adjacent to the bleeding organ — localizing the source, and a $\textbf{hematocrit effect}$ (dependent layering) and active contrast extravasation indicating ongoing hemorrhage. The cavity's anatomy directs the search: fluid collects in the most dependent and capacious recesses — the hepatorenal fossa (Morison pouch), the paracolic gutters, and the pelvis (rectovesical or rectouterine pouch) — and the falciform ligament, mesenteric root, and transverse mesocolon channel its spread, so a small volume is hunted in these reflections. $\textbf{Pneumoperitoneum}$ is read on lung/wide windows to detect tiny extraluminal gas locules; free intraperitoneal air after a non-operative interval signals hollow-viscus perforation, and its distribution (subdiaphragmatic, periportal, tracking along the falciform ligament) and any associated bowel-wall defect or focal fluid help localize the site.

Infection and malignancy are the principal pathologic processes coating the peritoneum. $\textbf{Peritonitis}$ and intraperitoneal $\textbf{abscess}$ present as loculated, rim-enhancing fluid collections, often gas-containing, with thickened enhancing peritoneum and stranding, demanding source control and drainage. $\textbf{Peritoneal carcinomatosis}$ — most often from ovarian, gastric, colorectal, pancreatic, or appendiceal primaries — is recognized by nodular or plaque-like peritoneal and omental thickening, the confluent soft-tissue "$\textbf{omental cake}$," scalloping of the visceral surfaces of the liver and spleen, and ascites that is frequently disproportionate to the apparent tumor burden. $\textbf{Pseudomyxoma peritonei}$, from a mucinous appendiceal or ovarian neoplasm, produces low-attenuation, often septated and calcifying mucinous material that characteristically scallops the hepatic and splenic margins. The systematic search inspects all peritoneal reflections, the omentum and mesentery, the diaphragmatic and subphrenic surfaces, the paracolic gutters, and the pelvis, because implants lodge preferentially where fluid stagnates. For oncologic follow-up, $\textbf{RECIST 1.1}$ conventions govern measurement, with the caveat that diffuse peritoneal disease and ascites are often non-measurable, so response is judged qualitatively and by associated measurable sites.

The failure modes blend physics and perception. Small-volume free fluid and tiny pneumoperitoneum are missed without scrutinizing dependent recesses and viewing wide windows; fluid attenuation is altered by averaging with adjacent structures, and a fluid-filled bowel loop simulates a loculated collection. Peritoneal implants are notoriously subtle, hidden against bowel and behind the dome of the diaphragm, making $\textbf{satisfaction of search}$ — stopping after the ascites is noted — the dominant cause of understaging. Conversely, normal omental fat and physiologic pelvic fluid in a premenopausal patient are overcalled. The decisive cognitive discipline is to treat unexplained ascites, particularly when loculated or disproportionate, as carcinomatosis or infection until the peritoneal surfaces have been deliberately and completely interrogated.